A $9.5M settlement resolves a lawsuit that alleged Natera failed to clearly inform patients of potential out-of-pocket costs ...

Natera’s updated analyst models now point to a higher Fair Value price target of US$344.33, up from US$282.14, which is roughly a 22% change in the modeled outcome. Analysts are tying this shift to ...

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

Natera (NTRA) is back in focus after the US Food and Drug Administration granted Breakthrough Device designation to its multi ...

Natera is rated Sell, as its valuation is stretched, with perfect execution priced in, despite looming competitive threats.

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, ...

FDA assessed data from 12 cancer types, considering sensitivity, specificity and cancer-signal origin; the program aims to ...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Natera Inc, a global leader in cell-free DNA and precision medicine, announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) ...

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, ...